Table 1.

BRCA1/2 founder mutation frequencies in AJ unselected prostate cancer cases and controls

	Ref #	185delAG (%)	5382insC (%)	6174delT (%)
Cases
Lehrer et al (1998)	13	0/60	n.t.	0/60
Hubert et al (1999)	14	2/87 (2.3%)	0/87	1/87 (1.1%)
Nastiuk et al (1999)	15	1/83 (1.2%)	n.t.	2/82 (2.4%)
Vazina et al (2000)	16	2/87 (2.3%)	2/60 (3.3%)*	1/86 (1.1%)
Hamel et al (this study)		0/146	0/146	2/146 (1.4%)
Total		5/463 (1.1%)	2/293 (0.68%)	6/461 (1.3%)
Controls
Struewing et al (1995)	2	8/858 (0.93%)	0/433	n.t.
Roa et al (1996)	3	34/3108 (1.1%)	4/3116 (0.13%)	47/3085 (1.5%)
Oddoux et al (1996)	4	n.t.	n.t.	12/1255 (0.96%)
Struewing et al (1997)†	8	41/5318 (0.77%)	20/5318 (0.38%)	59/5087 (1.2%)
Hubert et al (1999)	14	2/87 (2.3%)	0/87	1/87 (1.1%)
Total		85/9371 (0.91%)	24/8867 (0.27%)	119/9514 (1.3%)
Overall OR (95%CI)		1.2 (0.38–2.9)	2.5 (0.29–10)	1.0 (0.37–2.4)
P Value (2-sided)		0.62	0.20	0.83

n.t. Not tested Odds ratios were calculated according to the method of Gart. 95% confidence intervals were calculated using the exact Clopper-Pearson method and P values are two-sided Fisher exact tests. *This frequency was reported as significantly different from observations in a control population in the original publication. †Data from this publication were used as control by Vazina et al, 2000.